Novanta (NASDAQ:NOVT) CEO Matthijs Glastra Sells 6,500 Shares of Stock

Novanta Inc. (NASDAQ:NOVT) CEO Matthijs Glastra sold 6,500 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $161.13, for a total value of $1,047,345.00. Following the completion of the sale, the chief executive officer directly owned 29,761 shares of the company’s stock, valued at approximately $4,795,389.93. This represents a 17.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Matthijs Glastra also recently made the following trade(s):

• On Tuesday, May 12th, Matthijs Glastra sold 7,500 shares of Novanta stock. The shares were sold at an average price of $150.43, for a total transaction of $1,128,225.00.
• On Friday, April 17th, Matthijs Glastra sold 6,500 shares of Novanta stock. The shares were sold at an average price of $130.05, for a total transaction of $845,325.00.

Novanta Stock Down 10.3%

NOVT stock opened at $147.85 on Wednesday. The stock has a market capitalization of $5.58 billion, a PE ratio of 107.14 and a beta of 1.67. Novanta Inc. has a 52 week low of $98.27 and a 52 week high of $171.85. The company has a quick ratio of 2.69, a current ratio of 3.56 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average of $153.70 and a 200 day moving average of $137.75.

Novanta (NASDAQ:NOVT) last issued its quarterly earnings results on Monday, May 11th. The technology company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.03. Novanta had a net margin of 5.35% and a return on equity of 12.06%. The business had revenue of $257.71 million for the quarter, compared to analyst estimates of $253.40 million. During the same quarter in the prior year, the business posted $0.74 EPS. Novanta’s revenue for the quarter was up 10.4% compared to the same quarter last year. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q2 2026 guidance at 0.810-0.860 EPS. Sell-side analysts forecast that Novanta Inc. will post 3.59 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on NOVT shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Novanta in a research note on Friday, April 17th. Wall Street Zen raised Novanta from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Robert W. Baird set a $180.00 price target on shares of Novanta in a report on Tuesday, June 9th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $180.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NOVT. Danske Bank A S purchased a new position in shares of Novanta during the 3rd quarter valued at approximately $40,000. Allworth Financial LP grew its position in Novanta by 978.4% during the fourth quarter. Allworth Financial LP now owns 399 shares of the technology company’s stock valued at $47,000 after buying an additional 362 shares during the period. EverSource Wealth Advisors LLC grew its position in Novanta by 120.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 427 shares of the technology company’s stock valued at $51,000 after buying an additional 233 shares during the period. ANTIPODES PARTNERS Ltd purchased a new position in Novanta in the fourth quarter valued at $53,000. Finally, Harbor Investment Advisory LLC acquired a new position in shares of Novanta in the second quarter worth about $54,000. 98.35% of the stock is owned by institutional investors and hedge funds.

About Novanta

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.